ArtsAutosBooksBusinessEducationEntertainmentFamilyFashionFoodGamesGenderHealthHolidaysHomeHubPagesPersonal FinancePetsPoliticsReligionSportsTechnologyTravel

Interesting facts and history of abortion pill

Updated on August 14, 2008

The invention and discovery of abortion pill

The invention: RU-486 was the first commercially available drug that prevented fertilized eggs from implanting themselves in the walls of women’s uteruses.The people behind the invention:

Étienne-Émile Baulieu , a French biochemist and endocrinologist

Georges Teutsch, a French chemist

Alain Bélanger, a French chemist

Daniel Philibert, a French physicist and pharmacologist

Developing and Testing

In 1980, Alain Bélanger, a research chemist, was working with Georges Teutsch at Roussel Uclaf, a French pharmaceutical company. Teutsch and Bélanger were interested in understanding how changes in steroids affect the chemicals ability to bind to their steroid receptors. (Receptors are molecules on cells that can bind with certain chemical substances such as hormones. Receptors therefore act as connecting links to promote or prevent specific bodily activities or processes.) Bélanger synthesized several steroids that bonded to steroid receptors. Among these steroids was a compound that came to be called "RU-486." Another member of the research project, Daniel Philibert, found that RU-486 blocked the activities of progesterone by binding tightly to the progesterone receptor. Progesterone is a naturally occurring steroid hormone that prepares the wall of the uterus to accept a fertilized egg. Once this is done, the egg can become implanted and can begin to develop. The hormone also prevents the muscles of the uterus from contracting, which might cause the uterus to reject the egg. Therefore RU-486, by acting as a kind of shield between hormone and receptor, essentially stopped the progesterone from doing its job. At the time, Teutsch's group did not consider that RU-486 might be useful for deliberately interrupting human pregnancy. It was Étienne-Émile Baulieu, a biochemist and endocrinologist and a consultant for Roussel Uclaf, who made this connection. He persuaded the company to test RU-486 for its effects on fertility control. Many tests were performed on rabbits, rats, and monkeys; they showed that, even in the presence of progesterone, RU-486 could prevent secretory tissue from forming in the uterus, could change the timing of the menstrual cycle, and could terminate a pregnancy- that is, cause an abortion. The compound also seemed to be nontoxic, even in high doses.

In October of 1981, Baulieu began testing the drug with human volunteers. By 1985, major tests of RU-486 were being done in France, Great Britain, The Netherlands, Sweden, and China. When a relatively low dose of RU-486 was given orally, there was an 85 percent success rate in ending pregnancy; the woman's body expelled the embryo and all the endometrial surface. Researchers found that if a low dose of a prostaglandin (a hormonelike substance that causes the smooth muscles of the uterus to contract, thereby expelling the embryo) was given two days later, the success rate rose to 96 percent. There were few side effects, and the low doses of RU-486 did not interfere with the actions of other steroid hormones that are necessary to keep the body working. In the March, 1990, issue of The New England Journal of Medicine, Baulieu and his coworkers reported that with one dose of RU-486, followed in thirty-six to forty-eight hours with a low dose of prostaglandin, 96 percent of the 2,040 women they studied had a complete abortion with few side effects. The women were monitored after receiving the prostaglandin to watch for side effects, which included nausea, vomiting, abdominal pain, and diarrhea. When they returned for a later checkup, fewer than 2 percent of the women complained of side effects. The researchers used two different prostaglandins; they found that one caused a quicker abortion but also brought about more pain and a longer period of bleeding.

Using the drug

In September, 1988, the French government approved the distribution of RU-486 for use in government-controlled clinics. The next month, however, Roussel Uclaf stopped selling the drug because people opposed to abortion did not want RU-486 to be available and were threatening to boycott the company. Then, however, there were threats and pressure from the other side. For example, members of the World Congress of Obstetrics and Gynecology announced that they might boycott Roussel Uclaf if it did not make RU-486 available. The French government, which controlled a 36 percent interest in Roussel Uclaf, ordered the company to start distributing the drug once more. By the fall of 1989, more than one-fourth of all early abortions in France were being done with RU-486 and a prostaglandin. The French government began helping to pay the cost of using RU-486 in 1990.Testing for approval of RU-486 was completed in Great Britain and The Netherlands, but Roussel Uclaf's parent company, Hoechst AG, did not try to market the drug there or in any other country outside France. (In the United States, government regulations did not allow RU-486 to be tested using government funds.) Medical researchers believe that RU-486 may be useful not only for abortions but also in other ways. For example, it may help in treating certain breast cancers and other tumors. RU-486 is also being investigated as a possible treatment for glaucoma-to lower pressure in the eye that may be caused by a high level of steroid hormone. It may be useful in promoting the healing of skin wounds and softening the cervix at birth, easing delivery. Researchers hope as well that some form of RU-486 may prove useful as a contraceptive- that is, not to prevent a fertilized egg from implanting itself in the mother's uterus but to prevent ovulation in the first place.


Groups opposed to abortion rights have spoken out against RU- 486, while those who favor the right to abortion have urged its acceptance. The drug has been approved for use in China as well as in France. In the United States, however, the government has avoided giving its approval to the drug. Officials of theWorld Health Organization (WHO) have argued that RU-486 could prevent the deaths of women who undergo botched abortions. Under international law,WHOhas the right to take control of the drug and make it available in poor countries at low cost. Because of the controversy surrounding the drug, however,WHOcalled for more testing to ensure that RU-486 is quite safe for women.


    0 of 8192 characters used
    Post Comment

    • profile image


      9 years ago


      where did you get the information from ?


    This website uses cookies

    As a user in the EEA, your approval is needed on a few things. To provide a better website experience, uses cookies (and other similar technologies) and may collect, process, and share personal data. Please choose which areas of our service you consent to our doing so.

    For more information on managing or withdrawing consents and how we handle data, visit our Privacy Policy at:

    Show Details
    HubPages Device IDThis is used to identify particular browsers or devices when the access the service, and is used for security reasons.
    LoginThis is necessary to sign in to the HubPages Service.
    Google RecaptchaThis is used to prevent bots and spam. (Privacy Policy)
    AkismetThis is used to detect comment spam. (Privacy Policy)
    HubPages Google AnalyticsThis is used to provide data on traffic to our website, all personally identifyable data is anonymized. (Privacy Policy)
    HubPages Traffic PixelThis is used to collect data on traffic to articles and other pages on our site. Unless you are signed in to a HubPages account, all personally identifiable information is anonymized.
    Amazon Web ServicesThis is a cloud services platform that we used to host our service. (Privacy Policy)
    CloudflareThis is a cloud CDN service that we use to efficiently deliver files required for our service to operate such as javascript, cascading style sheets, images, and videos. (Privacy Policy)
    Google Hosted LibrariesJavascript software libraries such as jQuery are loaded at endpoints on the or domains, for performance and efficiency reasons. (Privacy Policy)
    Google Custom SearchThis is feature allows you to search the site. (Privacy Policy)
    Google MapsSome articles have Google Maps embedded in them. (Privacy Policy)
    Google ChartsThis is used to display charts and graphs on articles and the author center. (Privacy Policy)
    Google AdSense Host APIThis service allows you to sign up for or associate a Google AdSense account with HubPages, so that you can earn money from ads on your articles. No data is shared unless you engage with this feature. (Privacy Policy)
    Google YouTubeSome articles have YouTube videos embedded in them. (Privacy Policy)
    VimeoSome articles have Vimeo videos embedded in them. (Privacy Policy)
    PaypalThis is used for a registered author who enrolls in the HubPages Earnings program and requests to be paid via PayPal. No data is shared with Paypal unless you engage with this feature. (Privacy Policy)
    Facebook LoginYou can use this to streamline signing up for, or signing in to your Hubpages account. No data is shared with Facebook unless you engage with this feature. (Privacy Policy)
    MavenThis supports the Maven widget and search functionality. (Privacy Policy)
    Google AdSenseThis is an ad network. (Privacy Policy)
    Google DoubleClickGoogle provides ad serving technology and runs an ad network. (Privacy Policy)
    Index ExchangeThis is an ad network. (Privacy Policy)
    SovrnThis is an ad network. (Privacy Policy)
    Facebook AdsThis is an ad network. (Privacy Policy)
    Amazon Unified Ad MarketplaceThis is an ad network. (Privacy Policy)
    AppNexusThis is an ad network. (Privacy Policy)
    OpenxThis is an ad network. (Privacy Policy)
    Rubicon ProjectThis is an ad network. (Privacy Policy)
    TripleLiftThis is an ad network. (Privacy Policy)
    Say MediaWe partner with Say Media to deliver ad campaigns on our sites. (Privacy Policy)
    Remarketing PixelsWe may use remarketing pixels from advertising networks such as Google AdWords, Bing Ads, and Facebook in order to advertise the HubPages Service to people that have visited our sites.
    Conversion Tracking PixelsWe may use conversion tracking pixels from advertising networks such as Google AdWords, Bing Ads, and Facebook in order to identify when an advertisement has successfully resulted in the desired action, such as signing up for the HubPages Service or publishing an article on the HubPages Service.
    Author Google AnalyticsThis is used to provide traffic data and reports to the authors of articles on the HubPages Service. (Privacy Policy)
    ComscoreComScore is a media measurement and analytics company providing marketing data and analytics to enterprises, media and advertising agencies, and publishers. Non-consent will result in ComScore only processing obfuscated personal data. (Privacy Policy)
    Amazon Tracking PixelSome articles display amazon products as part of the Amazon Affiliate program, this pixel provides traffic statistics for those products (Privacy Policy)